These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
415 related articles for article (PubMed ID: 32949719)
1. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents. Yang X; Hou Z; Wang D; Mou Y; Guo C Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719 [TBL] [Abstract][Full Text] [Related]
2. Novel Pyrazoloquinolin-2-ones: Design, synthesis, docking studies, and biological evaluation as antiproliferative EGFR-TK inhibitors. Elbastawesy MAI; Aly AA; Ramadan M; Elshaier YAMM; Youssif BGM; Brown AB; El-Din A Abuo-Rahma G Bioorg Chem; 2019 Sep; 90():103045. PubMed ID: 31212178 [TBL] [Abstract][Full Text] [Related]
3. Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies. Kiriwan D; Seetaha S; Jiwacharoenchai N; Tabtimmai L; Sousa SF; Songtawee N; Choowongkomon K Chem Biol Drug Des; 2022 Mar; 99(3):456-469. PubMed ID: 34923743 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and Anticancer Activity of Novel Indole Derivatives as Dual EGFR/SRC Kinase Inhibitors. Olgen S; Kaleli SNB; Karaca BT; Demirel UU; Bristow HK Curr Med Chem; 2024; 31(24):3798-3817. PubMed ID: 37365789 [TBL] [Abstract][Full Text] [Related]
5. Synthesis, anticancer and apoptosis-inducing activities of quinazoline-isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies. El-Azab AS; Al-Dhfyan A; Abdel-Aziz AA; Abou-Zeid LA; Alkahtani HM; Al-Obaid AM; Al-Gendy MA J Enzyme Inhib Med Chem; 2017 Dec; 32(1):935-944. PubMed ID: 28718672 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC. Kim DM; Kim MJ; Moon JH; Lee EY; Hong JK; Lee S; Koh DI; Ryu YS; Kim SM; Jung SA; Shin JS; Kim J; Park YS; Hong SW; Lee SH; Jung J; Park SS; Kim DY; Kim EH; Jeong HR; Gong JH; Kim J; Chan Kim S; Yu HN; Ki SY; Kim TW; Jin DH Biochem Biophys Res Commun; 2020 Jun; 527(1):305-310. PubMed ID: 32446385 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors. Srour AM; Ahmed NS; Abd El-Karim SS; Anwar MM; El-Hallouty SM Bioorg Med Chem; 2020 Sep; 28(18):115657. PubMed ID: 32828424 [TBL] [Abstract][Full Text] [Related]
8. Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro. Biegański P; Godel M; Riganti C; Kawano DF; Kopecka J; Kowalski K Bioorg Chem; 2022 Feb; 119():105514. PubMed ID: 34864281 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors. Abdelsalam EA; Zaghary WA; Amin KM; Abou Taleb NA; Mekawey AAI; Eldehna WM; Abdel-Aziz HA; Hammad SF Bioorg Chem; 2019 Aug; 89():102985. PubMed ID: 31121559 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185 [TBL] [Abstract][Full Text] [Related]
11. Design and Synthesis of Non-Covalent Imidazo[1,2- Kumar M; Joshi G; Arora S; Singh T; Biswas S; Sharma N; Bhat ZR; Tikoo K; Singh S; Kumar R Molecules; 2021 Mar; 26(5):. PubMed ID: 33803355 [TBL] [Abstract][Full Text] [Related]
12. In Vitro and In Silico Evaluation of Anticancer Activity of New Indole-Based 1,3,4-Oxadiazoles as EGFR and COX-2 Inhibitors. Sever B; Altıntop MD; Özdemir A; Akalın Çiftçi G; Ellakwa DE; Tateishi H; Radwan MO; Ibrahim MAA; Otsuka M; Fujita M; Ciftci HI; Ali TFS Molecules; 2020 Nov; 25(21):. PubMed ID: 33171861 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors. Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743 [TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAF Al-Wahaibi LH; Gouda AM; Abou-Ghadir OF; Salem OIA; Ali AT; Farghaly HS; Abdelrahman MH; Trembleau L; Abdu-Allah HHM; Youssif BGM Bioorg Chem; 2020 Nov; 104():104260. PubMed ID: 32920363 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo. Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535 [TBL] [Abstract][Full Text] [Related]
16. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells. Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M). Shaheen MA; El-Emam AA; El-Gohary NS Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080 [TBL] [Abstract][Full Text] [Related]